Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Cardiac Biomarkers Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The cardiac biomarkers market has observed substantial expansion in recent years. It is anticipated to grow from $21.19 billion in 2025 to $24.22 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.3%. The market’s past growth can be attributed to factors such as a rise in cardiovascular disease incidence, the broadening of emergency cardiac care services, increased uptake of laboratory diagnostics, the expanding utilization of biomarker-based diagnoses, and enhancements in immunoassay technologies.
The cardiac biomarkers market is anticipated to experience substantial growth in the coming years, with its size projected to reach $42.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.9%. This expansion throughout the forecast period stems from factors such as the heightened need for rapid cardiac diagnostics, the increasing acceptance of decentralized testing models, the wider implementation of preventive cardiology screening, rising investments in advanced diagnostic platforms, and the greater integration of digital health analytics. Key trends expected during this period include the growing adoption of high-sensitivity troponin tests, the expanded utilization of point-of-care cardiac testing, an escalating demand for rapid diagnostic kits, the broadening of multiplex cardiac biomarker panels, and a reinforced emphasis on early cardiac risk identification.
Get A Free Sample Report With In-Depth Market Insights:
Cardiac Biomarkers Market Growth Backed By Core Demand Fundamentals
Increasing healthcare spending is anticipated to fuel the expansion of the cardiac biomarker market in the future. Healthcare spending encompasses all expenses linked to delivering health services, family planning initiatives, nutritional support, and health-focused emergency assistance. The investment in cardiac biomarkers within healthcare aims to enhance early disease identification, offer tailored treatments, and optimize resource deployment, potentially leading to a decrease in the overall expenses connected to cardiovascular conditions. As an illustration, in May 2024, a report from the Office for National Statistics, a UK-based government department, indicated that overall healthcare expenditure saw a 5.6% nominal increase between 2022 and 2023, significantly higher than the mere 0.9% growth recorded in 2022. Consequently, the increase in healthcare spending is a key factor propelling the expansion of the cardiac biomarker market.
Cardiac Biomarkers Market Segment Landscape: Which Areas Lead Development?
The cardiac biomarkers market covered in this report is segmented –
1) By Biomarker Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA)
2) By Location Of Testing: Point Of Care Testing, Laboratory Testing
3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications
4) By End User: Hospitals, Specialty Clinics
Subsegments:
1) By Creatine Kinase (CK-Mb): CK-Mb Test Kits, CK-Mb Diagnostic Panels
2) By Troponins: Troponin I Test Kits, Troponin T Test Kits, Troponin Diagnostic Panels
3) By Myoglobin: Myoglobin Test Kits, Myoglobin Diagnostic Panels
4) By Natriuretic Peptides (BNP And NT-proBNP): BNP Test Kits, NT-ProBNP Test Kits, Natriuretic Peptides Diagnostic Panels
5) By Ischemia Modified Albumin (IMA): IMA Test Kits, IMA Diagnostic Panels
Cardiac Biomarkers Market Growth Trends Reshaping The Competitive Landscape
Leading firms within the cardiac biomarker markets are concentrating on creating novel assays to broaden their product offerings, thereby enhancing patient care and addressing gaps in medical requirements. These pioneering biomarker assays propel progress in cardiac diagnostics, boosting precision and extending diagnostic functionalities. A case in point is October 2023, when Shenzhen Mindray Bio-Medical Electronics Co., Ltd., a medical devices and solutions provider based in China, introduced two new cardiac biomarkers: high-sensitivity troponin I (hs-cTnI) and NT-proBNP. These additions strengthen Mindray’s extensive collection of cardiac biomarkers, utilized for detecting and treating cardiovascular diseases (CVDs).
Cardiac Biomarkers Market Competitive Overview And Top Companies
Major companies operating in the cardiac biomarkers market are F. Hoffmann-La Roche AG, Siemens Healthineers AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Bio-Rad Laboratories Inc, bioMérieux SA, QuidelOrtho Corporation, Randox Laboratories Ltd, Becton Dickinson and Company, Tosoh Corporation, PerkinElmer Inc, Grifols S.A., DiaSorin S.p.A., Sysmex Corporation, Lepu Medical Technology (Beijing) Co. Ltd, Mindray Bio-Medical Electronics Co. Ltd, Fujirebio Holdings Inc, Euroimmun AG, Beckman Coulter Inc, Trinity Biotech plc
View The Full Cardiac Biomarkers Market Report:
Cardiac Biomarkers Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the cardiac biomarkers market in 2025. The regions covered in the cardiac biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
